IBDEI0RE ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,12851,0)
 ;;=L30.4^^53^582^144
 ;;^UTILITY(U,$J,358.3,12851,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12851,1,3,0)
 ;;=3^Erythema Intertrigo
 ;;^UTILITY(U,$J,358.3,12851,1,4,0)
 ;;=4^L30.4
 ;;^UTILITY(U,$J,358.3,12851,2)
 ;;=^5009157
 ;;^UTILITY(U,$J,358.3,12852,0)
 ;;=L30.8^^53^582^135
 ;;^UTILITY(U,$J,358.3,12852,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12852,1,3,0)
 ;;=3^Dermatitis NEC
 ;;^UTILITY(U,$J,358.3,12852,1,4,0)
 ;;=4^L30.8
 ;;^UTILITY(U,$J,358.3,12852,2)
 ;;=^5009158
 ;;^UTILITY(U,$J,358.3,12853,0)
 ;;=L30.9^^53^582^136
 ;;^UTILITY(U,$J,358.3,12853,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12853,1,3,0)
 ;;=3^Dermatitis,Unspec
 ;;^UTILITY(U,$J,358.3,12853,1,4,0)
 ;;=4^L30.9
 ;;^UTILITY(U,$J,358.3,12853,2)
 ;;=^5009159
 ;;^UTILITY(U,$J,358.3,12854,0)
 ;;=L40.0^^53^582^253
 ;;^UTILITY(U,$J,358.3,12854,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12854,1,3,0)
 ;;=3^Psoriasis Vulgaris
 ;;^UTILITY(U,$J,358.3,12854,1,4,0)
 ;;=4^L40.0
 ;;^UTILITY(U,$J,358.3,12854,2)
 ;;=^5009160
 ;;^UTILITY(U,$J,358.3,12855,0)
 ;;=L40.1^^53^582^256
 ;;^UTILITY(U,$J,358.3,12855,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12855,1,3,0)
 ;;=3^Pustulosis Psoriasis,Generalized
 ;;^UTILITY(U,$J,358.3,12855,1,4,0)
 ;;=4^L40.1
 ;;^UTILITY(U,$J,358.3,12855,2)
 ;;=^5009161
 ;;^UTILITY(U,$J,358.3,12856,0)
 ;;=L40.2^^53^582^11
 ;;^UTILITY(U,$J,358.3,12856,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12856,1,3,0)
 ;;=3^Acrodermatitis Continua
 ;;^UTILITY(U,$J,358.3,12856,1,4,0)
 ;;=4^L40.2
 ;;^UTILITY(U,$J,358.3,12856,2)
 ;;=^5009162
 ;;^UTILITY(U,$J,358.3,12857,0)
 ;;=L40.3^^53^582^255
 ;;^UTILITY(U,$J,358.3,12857,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12857,1,3,0)
 ;;=3^Pustulosis Palmaris et Plantaris
 ;;^UTILITY(U,$J,358.3,12857,1,4,0)
 ;;=4^L40.3
 ;;^UTILITY(U,$J,358.3,12857,2)
 ;;=^5009163
 ;;^UTILITY(U,$J,358.3,12858,0)
 ;;=L40.4^^53^582^157
 ;;^UTILITY(U,$J,358.3,12858,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12858,1,3,0)
 ;;=3^Guttate Psoriasis
 ;;^UTILITY(U,$J,358.3,12858,1,4,0)
 ;;=4^L40.4
 ;;^UTILITY(U,$J,358.3,12858,2)
 ;;=^5009164
 ;;^UTILITY(U,$J,358.3,12859,0)
 ;;=L40.8^^53^582^252
 ;;^UTILITY(U,$J,358.3,12859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12859,1,3,0)
 ;;=3^Psoriasis NEC
 ;;^UTILITY(U,$J,358.3,12859,1,4,0)
 ;;=4^L40.8
 ;;^UTILITY(U,$J,358.3,12859,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,12860,0)
 ;;=L40.9^^53^582^254
 ;;^UTILITY(U,$J,358.3,12860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12860,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,12860,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,12860,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,12861,0)
 ;;=L50.9^^53^582^286
 ;;^UTILITY(U,$J,358.3,12861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12861,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,12861,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,12861,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,12862,0)
 ;;=L53.8^^53^582^147
 ;;^UTILITY(U,$J,358.3,12862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12862,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,12862,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,12862,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,12863,0)
 ;;=L53.9^^53^582^146
 ;;^UTILITY(U,$J,358.3,12863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12863,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,12863,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,12863,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,12864,0)
 ;;=L54.^^53^582^145
 ;;^UTILITY(U,$J,358.3,12864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,12864,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
